Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Update

Caribou Biosciences, Inc. (NASDAQ:CRBU) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 8,620,000 shares, a growth of 16.2% from the November 15th total of 7,420,000 shares. Currently, 10.9% of the shares of the company are short sold. Based on an average daily volume of 1,280,000 shares, the days-to-cover ratio is currently 6.7 days.

Institutional Investors Weigh In On Caribou Biosciences

Several large investors have recently made changes to their positions in the company. PFM Health Sciences LP raised its stake in Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after purchasing an additional 223,299 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after buying an additional 536,162 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares during the last quarter. FMR LLC grew its position in Caribou Biosciences by 7.4% in the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after acquiring an additional 109,606 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Caribou Biosciences in the 2nd quarter worth approximately $2,432,000. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Price Performance

NASDAQ CRBU remained flat at $1.91 during trading hours on Monday. The company had a trading volume of 1,297,024 shares, compared to its average volume of 1,699,327. Caribou Biosciences has a one year low of $1.50 and a one year high of $8.33. The business’s 50-day moving average is $2.09 and its 200-day moving average is $2.04. The stock has a market cap of $172.96 million, a P/E ratio of -1.16 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Sell-side analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Citigroup decreased their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $10.20.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.